Autoinflammatory & rare systemic diseases
Efficacy and glucocorticoid sparing of dupilumab in IgG4-related disease: a case series and literature review
Authors' conclusion
These preliminary findings need to be confirmed, but may offer arguments in favour of a possible efficacy of dupilumab in the treatment of IgG4-RD.
Study context
- Population
- French patients meeting 2019 ACR/EULAR criteria or comprehensive diagnostic criteria for igG4-related disease (IgG4-RD), treated with dupilumab
- Participants
- 7 patients
- Outcome
- Disease control assessed by the IgG4-Related Disease Responder Index
Methodological detailsmulticentre, standardised questionnaires, Indication for dupilumab: severe asthma, nasosinusal polyps and/or atopic dermatitis
- Multicentre
- Standardised questionnaires
- Indication for dupilumab: severe asthma, nasosinusal polyps and/or atopic dermatitis
Main finding
As reported in the abstract
Response (IgG4-RD Responder Index)
- Complete response
- 3 patients
- Partial response
- 4 patients
- Glucocorticoids (GC) sparing achieved
- all cases
Observational data: associations, not effects.
Further findings
Literature review: partial or complete reduction of the disorder with GC sparing
- Cases with partial or complete reduction and GC sparing
- 9 of 10 reported cases
Original publication
Efficacy and glucocorticoid sparing of dupilumab in IgG4-related disease: a case series and literature review. Clin Exp Rheumatol. Published 29 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →